MedTrace Logo

Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma

NCT04073147 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2022-01-19

No results posted yet for this study

Summary

This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma.

Conditions

  • Primary CNS Lymphoma

Interventions

DRUG

Venetoclax

Venetoclax per os

DRUG

Obinutuzumab

ObintuzumabIV

Sponsors & Collaborators

  • University Hospital Freiburg

    collaborator OTHER

  • Klinikum Stuttgart

    lead OTHER

Principal Investigators

  • Gerald Illerhaus, Prof · Klinikum der Landeshauptstadt Stuttgart gKAö

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-12
Primary Completion
2021-11-25
Completion
2021-11-25

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04073147 on ClinicalTrials.gov